Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristina Ellwanger

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid LeukemiaUwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Mabs|July 30, 2021
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumorsSusanne Wingert, Uwe Reusch, Stefan Knackmuss, et al.
Plos One|May 4, 2010
Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2Jochen Schulze, Sebastian Seitz, Hiroaki Saito, et al.
Leukemia|January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid LeukemiaUwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Mabs|July 30, 2021
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumorsSusanne Wingert, Uwe Reusch, Stefan Knackmuss, et al.
Plos One|May 4, 2010
Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2Jochen Schulze, Sebastian Seitz, Hiroaki Saito, et al.
Leukemia|January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Pageof 2